The detection of macroprolactin by precipitation and ultrafiltration methods by Beda-Maluga, Karolina et al.
529
PRACE ORYGINALNE/ORIGINAL PAPERS
Endokrynologia Polska/Polish Journal of Endocrinology
Tom/Volume 62; Numer/Number 6/2011
ISSN 0423–104X
The detection of macroprolactin by precipitation 
and ultrafiltration methods
 Wykrywanie makroprolaktyny za pomocą metody precypitacji i ultrafiltracji
Karolina Beda-Maluga1, Hanna Pisarek1, Jan Komorowski2, Marek Pawlikowski1, Jacek Świętosławski1, 
Katarzyna Winczyk1
1Department of Neuroendocrinology, Medical University of Lodz, Poland
2Department of Clinical Endocrinology, First Chair of Endocrinology, Medical University of Lodz, Poland
Abstract
Background: Prolactin (PRL) exists in human blood in several molecular forms. Macroprolactin (MaPRL), which most often consists of 
monomeric PRL and immunoglobulin G, has the highest molecular weight but no biological activity. Immunoassays do not distinguish 
MaPRL from monomeric PRL, what can lead to an incorrect diagnosis of hyperprolactinaemia. The most commonly used technique to 
separate the isoforms of PRL is precipitation with polyethylene glycol (PEG). Another technique — ultrafiltration — seems to be useful 
in MaPRL detection. The aim of this study was to evaluate the occurrence of MaPRL in hyperprolactinaemic patients and to compare the 
results obtained by precipitation and ultrafiltration.
Material and methods: The study was conducted on 120 sera obtained from patients hospitalised in the Department of Clinical Endocri-
nology, Medical University of Lodz, in whom PRL concentration was above 30 ng/mL Of these 120 patients, 25 had pituitary adenoma, 
52 had polycystic ovary syndrome (PCOS), and 43 had idiopathic hyperprolactinaemia (HPRL). Macroprolactin was detected using two 
methods: precipitation with PEG and ultrafiltration. Concentration of PRL was measured by Immulite 1000 immunoassay (Siemens).
Results: We detected a predominance of MaPRL in ten patients (three with macroprolactinoma, three with PCOS and four with HPRL) 
using precipitation and ultrafiltration. Positive correlation and diagnostic concordance between the results of precipitation and ultrafiltra-
tion were noted, especially in the group with functional hyperprolactinaemia. In half of the patients with macroprolactinaemia, and in 12 
of the 110 subjects without significant amounts of MaPRL, real PRL concentration was within the reference range. 
Conclusions: MaPRL is not a significant clinical problem in the studied population. However, in patients with hyperprolactinaemia, 
especially non-organic, screening for macroprolactinaemia should be performed. The effectiveness of the precipitation and ultrafiltra-
tion methods for detecting MaPRL is comparable in functional hyperprolactinaemia, but the usefulness of ultrafiltration in patients with 
pituitary adenoma requires further examination. (Pol J Endocrinol 2011; 62 (6): 529–536)
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Streszczenie
Wstęp: We krwi ludzkiej występuje kilka izoform prolaktyny (PRL). Największą z nich, ale niewykazującą aktywności biologicznej jest 
makroprolaktyna (MaPRL). Stanowi ona połączenie monomerycznej PRL z immunoglobuliną G. Zestawy diagnostyczne do pomiaru stęże-
nia PRL nie odróżniają MaPRL od postaci monomerycznej, co może prowadzić do błędnego rozpoznania hiperprolaktynemii. Najczęściej 
stosowaną techniką rozdziału izoform PRL jest precypitacja za pomocą glikolu polietylenowego (PEG). Przydatną w wykrywaniu MaPRL 
wydaje się też być technika ultrafiltracji. Celem pracy była ocena częstości występowania MaPRL u pacjentów z hiperprolaktynemią oraz 
porównanie wyników uzyskanych za pomocą metody precypitacji i ultrafiltracji.
Materiał i metody: Surowice do badania uzyskano od 120 osób hospitalizowanych w Klinice Endokrynologii Uniwersytetu Medycznego 
w Łodzi, u których stężenie PRL było wyższe niż 30 ng/mL — 25 chorych z gruczolakiem przysadki, 52 kobiety z zespołem policystycz-
nych jajników (PCOS) i 43 osoby z hiperprolaktynemią idiopatyczną (HPRL). Do wykrywania MaPRL zastosowano metodę precypitacji 
PEG-iem i technikę ultrafiltracji. Stężenie PRL oznaczano na analizatorze Immulite 1000 (Siemens).
Wyniki: Za pomocą metod precypitacji i ultrafiltracji znaczące ilości MaPRL wykryto u 10 osób (3 z macroprolactinoma, 3 z PCOS i 4 z HPRL). 
Zaobserwowano dodatnią korelację oraz wysoką zgodność diagnostyczną pomiędzy wynikami obu metod, szczególnie w grupie osób 
z hiperprolaktynemią czynnościową. U połowy osób ze stwierdzoną makroprolaktynemią oraz u 12 spośród 110 osób bez znaczącej ilości 
MaPRL we krwi rzeczywiste (po usunięciu makroform hormonu) stężenie PRL mieściło się w zakresie wartości referencyjnych.
Wnioski: Makroprolaktyna nie stanowi znaczącego problemu klinicznego w badanej populacji. Jednakże u osób z hiperprolaktynemią, 
szczególnie pochodzenia nieorganicznego, powinno się wykonywać badania przesiewowe w kierunku makroprolaktynemii.
Skuteczność precypitacji i ultrafiltracji w wykrywaniu MaPRL jest porównywalna u osób z hiperprolaktynemią czynnościową, natomiast 
do określenia przydatności metody ultrafiltracji u pacjentów z gruczolakiem przysadki potrzebne są dalsze badania. 
(Endokrynol Pol 2011; 62 (6): 529–536)
Słowa kluczowe: prolaktyna, makroprolaktyny, hiperprolaktynemia, glikol polietylenowy, precypitacja, ultrafiltracja
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Introduction
The presence of various forms of prolactin (PRL) in 
human blood was described more than 30 years ago 
[1–3]. It was proved that PRL occurs mainly in three 
molecular forms: a monomeric PRL with molecular 
weight ~ 23 kDa; a larger form named “big PRL” 
(~50 kDa) and a “big, big PRL” with a molecular weight 
over 100 kDa which is also called macroprolactin 
(MaPRL). In the majority of cases, MaPRL consists of 
monomeric PRL connected with immunoglobulin; most 
frequently type G, although other forms which have 
a very high molecular mass such as conglomerates of 
glycosylated PRL have also been found in human se-
rum [4–8]. The predominant isoform of PRL in healthy 
people, and also in most individuals with hyperpro-
lactinaemia, is a monomeric molecule which amounts 
to more than 85% of circulating hormone. However, in 
some patients with hyperprolactinaemia, the dominant 
form becomes MaPRL, which in normal conditions does 
not exceed 2% of total serum PRL. It has been shown 
that MaPRL is biologically inactive because the large 
molecular size of this complex prevents its crossing 
through the capillary blood barrier and reaching target 
cells [9, 10]. Moreover, immunoglobulin connecting with 
specific epitops of PRL molecule may reduce the bind-
ing of the hormone to its receptors [11, 12]. On the other 
hand, most commercial immunoassays used to measure 
PRL level do not distinguish MaPRL from monomeric 
PRL, which can lead to an incorrect diagnosis of hyper-
prolactinaemia and the implementation of unnecessary 
imaging study and treatment. Cases where MaPRL 
predominates in human serum are called macropro-
lactinaemia. The percentage of hyperprolactinaemic 
patients with macroprolactinaemia has been studied 
several times, and ranges from 10% to 45% [13–17]. 
Among methods used to detect MaPRL, gel filtration 
chromatography (GFC) is acknowledged to be the gold 
standard, but its highly complex, time-consuming, and 
expensive procedure prohibits its use in routine screen-
ing for MaPRL [18–20]. 
The most widely applied alternative method is 
precipitation with polyethylene glycol (PEG). However, 
this relatively simple, rapid and cheap technique is 
not perfect because PEG can interfere with some PRL 
immunoassays and it can precipitate not only MaPRL 
but partially also monomeric PRL [18, 21, 22]. There-
fore, other methods of detecting MaPRL are still being 
sought. Recently, it has been shown that ultrafiltration 
based on physical separation of high weight molecules 
such as “big, big PRL” from the smaller isoforms of hor-
mone may be useful in screening for MaPRL [23–25].
In the present study, we detected MaPRL using the 
classical method of precipitation with polyethylene 
glycol, and also the ultrafiltration method. The aim of 
this study was to evaluate the occurrence of MaPRL 
in hyperprolactinaemic patients hospitalised in the 
University Hospital of Lodz and to compare the results 
obtained by using two MaPRL screening techniques.
Material and methods 
Patients
The study was conducted on 120 patients (110 women 
and 10 men) hospitalised in the Department of Clinical 
Endocrinology, Medical University of Lodz. In all the 
subjects, the concentration of PRL measured in a fasting 
state was above 30 ng/mL. Based on the clinical data 
and laboratory results, the following diagnoses were 
made: 25 cases of prolactinoma (12 macroadenomas 
and 13 microadenomas); and 95 patients with functional 
hyperprolactinaemia (52 women with polycystic ovary 
syndrome and 43 cases of idiopathic hyperprolacti-
naemia). Some of the patients with prolactinoma were 
treated pharmacologically before the examination using 
dopamine agonists (13 subjects) and three persons also 
underwent neurosurgical therapy. 
PRL immunoassay
Prolactin concentration was measured by enzyme-am-
plified chemiluminescent immunoassay (Immulite 
1000, Siemens). Analytical sensitivity of the assay is 
0.5 ng/mL. Intraassay coefficients of variation (CV) at 
the PRL concentration of 16.3 ng/mL is 6.1% and inte-
rassay CV at the concentration of 14.1 ng/mL is 9.6%. 
Reference ranges are 1.9–25.0 ng/mL for women and 
2.5–17.0 ng/mL for men.
Precipitation with PEG
Precipitation with PEG was performed according to the 
method proposed by Olukoga and Kane [18] and also 
followed a protocol recommended by the Diagnostic 
Products Corporation. Equal volumes of PEG (Sigma) 
and serum were mixed. The obtained solution was 
incubated at room temperature for 10 minutes and 
then a sample was centrifuged at 3,000 rpm for 30 min-
utes. Prolactin concentration was measured in 10-fold 
diluted, untreated serum (PRLtotal) and also in 10-fold 
diluted supernatant obtained after PEG precipitation 
(PRLPEG). The percentage ratio PRLPEG /PRLtotal was 
calculated. In accordance with most literature data [18, 
13, 26], a result equal to or below 40% was assumed 
to be predominance of MaPRL in the serum sample 
(macroprolactinaemic subjects). 
Ultrafiltration
Ultrafiltration process was performed according to the 
procedure described by Kavanagh-Wright [21, 27]. The 
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Microcon YM-100 ultrafilter (Millipore; membrane with 
cut-off 100 kDa of molecular mass) was used to separate 
macroforms of PRL. The serum samples (25 μl) were 
mixed with 475μl phosphate buffer saline (PBS) and 
were centrifuged at 3,000 rpm for 45 minutes. Prolac-
tin concentration was measured in filterable fraction 
of serum and in the original serum sample. Recovery 
hormone after ultrafiltration was calculated by divid-
ing the PRL concentration of ultrafiltrate by the PRL 
concentration of untreated serum.
Statistical analysis 
The data obtained from the experiment was recorded 
on Excel (MS Office 2007) worksheets. Basic descriptive 
statistics (mean, SE) were calculated. A statistical analy-
sis was performed using one-way ANOVA followed 
by Fisher’s t-test (LSD — least significant difference) 
method according to Statistica 9 computer program 
(licensed to the Medical University of Lodz). In the 
case of the analysis of data measured before and after 
PRL forms separation (precipitation and ultrafiltration 
methods), a pairwise test was applied. Additionally, 
the Pearson linear correlation coefficient (r) was deter-
mined, in the case of their statistical significance (p), and 
the equation of regression was calculated (y = ax + b). 
Statistical differences between the tested values were at 
a significance level of p < 0.05. The sensitivity, specificity 
and ROC curve were used as methods determining the 
precision of the diagnostic test.
Results
The clinical data of the patients and the mean of PRL 
levels (total, after PEG precipitation, and after ultrafiltra-
tion) are presented in Table I. As had been anticipated, 
the patients with prolactinomas had higher levels of 
total PRL than women with PCOS and HPRL. After the 
removal of PRL macroforms by precipitation or ultrafil-
tration methods, the values of the hormone in the group 
with pituitary adenomas remained the highest, and 
repeatedly exceeded the reference range. The means of 
PRL level in PCOS and HPRL groups were significantly 
lower, but were also above the reference range. The 
means of PRL recovery after PEG precipitation were 
significantly higher than the values of the hormone after 
ultrafiltration in most investigated groups. 
The recoveries of PRL after PEG precipitation, and 
after ultrafiltration, were compared by linear regression. 
We noted a positive correlation between the two meth-
ods for the whole studied group — patients with and 
without macroprolactinaemia together (Figure 1) and 
in the group without macroprolactinaemia (r = 0.3409, 
p < 0.001) but no correlation of PRL recoveries was 
observed in the group with macroprolactinaemia 
(r = –0.0489, p > 0.05).
In accordance with most literature data, the recovery 
of PRL after PEG treatment equal to or less than 40% 
indicates a prevalence of MaPRL in the examined serum 
sample. The limit of recovery PRL after ultrafiltration 
Table I. Clinical data and serum levels of PRL in subjects
Tabela I. Dane kliniczne i stężenia PRL we krwi badanych osób
Clinical diagnosis Prolactinoma (n = 25)
HPRL 
(n = 43) 
PCOS 
(n = 52)Macroadenoma (n = 12) Microadenoma (n = 13)
Mean values No treatment Treatment No treatment Treatment
Age [years] Min–max 40 ± 6.222–52
36 ± 2.8
24–45
34 ± 3.5
20–48
42 ± 4.6
23–54
28 ±1.2
17–60
26 ± 0.8
17–43
PRL [ng/mL] 3,322 ± 1,891.2 206 ± 94.9 148 ±16.9 86.2 ± 19.5 60 ± 3.1 57 ± 3.2
PRL min–max [ng/mL] 426 – 10,540 33 – 751 99 – 211 40 – 144 32 – 113 31 – 143
Recovery of PRL 
after PEG (%) 62 ± 10 97 ± 11.9 78 ± 2.4 85 ± 5.6 69 ± 1.9 68 ± 1.7
Recovery of PRL 
after UF [%] 43 ± 4.8 69 ± 9.1 60 ± 7.5 66 ± 8.8 60 ± 2.2 64 ± 2.0
PRLPEG [ng/mL] 1,421 ± 484.4 201 ± 102.7 121 ± 12.3 68 ± 17 43 ± 3.0 40 ± 2.7
PRL UF [ng/mL] 1,424 ± 784.0 131 ± 68.0 97 ± 15.7 47 ± 9.0 36 ± 1.6 36 ± 1.7
Number of pts 
having PRL 
conc. [ng/mL]
30–49.9 0 2 0 2 16 26
50–99.9 0 1 1 2 23 22
≥ 100 5 4 6 2 4 4
HPRL — idiopathic hyperprolactinaemia; PCOS — polycystic ovary syndrome; PRLPEG — prolactin level after PEG precipitation; PRLUF — prolactin level 
after ultrafiltration
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has not been quantified exactly in the literature [23–25]. 
In order to determine the precision of both diagnostic 
techniques for detecting MaPRL, i.e. PEG precipitation 
and ultrafiltration methods, the area under the ROC 
curve (AUC ROC) was used. The ROC curve describes 
the relationship between the true positive and the false 
positive results of examined methods (precipitation 
and ultrafiltration) for the different possible cut-off 
points of a diagnostic test (in our study — ultrafiltra-
tion method). The area under the ROC curve indicates 
the precision of the examined method (UF). The size 
of the area under the ROC curve indicates the power 
of a diagnostic test. It is generally accepted that the 
significant power of a diagnostic test is represented 
as a volume of AUC ROC of between 0.80–0.95. In our 
experiment, AUC ROC amounted to 0.91. The highest 
value of the swelling of the ROC curve has been ac-
cepted as a cut-off point — in our study the range of 
cut-off points of ultrafiltration was 38–40% (Figure 2). 
Additionally, the sensitivity curve and the specificity 
curve for UF were plotted. The cut-off point of UF was 
chosen near the intersection value of the sensitivity and 
specificity curves and demonstrated the high precision 
of the test (97%). In the used test, the cut-off point for 
ultrafiltration method was also in the range of 38–40% 
and those values were very similar to the cut-off point 
for PEG precipitation — 40% (Figure 3).
We performed a diagnostic concordance test, 
sometimes known as ‘test effectiveness’. It defines 
the percentage of truly positive and truly negative 
results in relation to all performed tests. It is assumed 
that a test with effectiveness of less than 80% is of no 
diagnostic usefulness. We found that the agreement 
between positive and negative results of precipitation 
and ultrafiltration methods was high and reached al-
most 97% (Table II).
Patients with macroprolactinaemia
Using the 40% limit for PEG precipitation and ultrafil-
tration, significant amounts of MaPRL were detected 
in ten patients among the 120 hyperprolactinaemic 
subjects (8.3%). Macroprolactin was found in 12% 
of patients with prolactinoma, 5.8% of women with 
Figure 1. Correlation between recoveries of PRL (%) after PEG precipitation and ultrafiltration methods. PEG — polyethylene glycol
Rycina 1. Współzależność odzysku PRL po precypitacji PEG-iem i odzysku po ultrafiltracji; PEG — glikol polietylenowy
Table II. Number of MaPRL “positive” or “negative” results 
basing on 40% criterion for both methods
Tabela II. Liczba wyników „pozytywnych” lub „negatywnych” 
dla MaPRL na podstawie 40% kryterium dla obu metod
Ultrafiltration 
(n = 120)
Precipitation (n = 120)
Positive results 
(PEG £ 40)
Negative results 
(PEG > 40)
Positive results 
(UF £ 40)
6 (5.0%) 3 (2.5%)
Negative results 
(UF > 40)
1 (0.8%) 110 (91.7%)
Diagnostic concordance 96.7%
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Figure 3. Sensitivity and specificity curves for ultrafiltration 
(regarding PEG precipitation cut-off point — 40%)
Rycina 3. Krzywe czułości i specyficzności dla ultrafiltracji 
(zgodnie z punktem odcięcia dla precypitacji PEG-iem — 40%)
Figure 2. ROC curve for precipitation and ultrafiltration 
methods
Rycina 2. Krzywa ROC dla metody precypitacji i ultrafiltracji
PCOS, and 9.3% of subjects with HPRL (Table III). In 
six patients (women with PCOS and HPRL), MaPRL 
was detected by both precipitation and ultrafiltration 
methods. In four of these cases, the recoveries of PRL 
after PEG treatment and after UF were very similar. 
In four other subjects (three men with adenoma and 
one woman with HPRL), we noted a disagreement 
between the results obtained by the precipitation 
and ultrafiltration methods: three patients were mac-
roprolactinaemic according to UF, and (another) one 
according to PEG. Moreover, three women with HPRL 
did not show clinical symptoms of increased PRL level 
(Table III).
After separating macroforms of PRL according to 
PEG precipitation results, the hormone concentration 
turned out to be in the reference range (established by 
the manufacturer) in half of the macroprolactinaemic 
patients (only women with PCOS and HPRL — patients 
no. 4, 5, 8, 9 and10 — Table III). 
Table III. Characteristics of patients with macroprolactinaemia
Tabela III. Charakterystyka pacjentów z makroprolatynemią
No. Sex/age Clinical diagnosis Clinical symptoms  of HPRL
PRL 
[ng/mL]
Post-PEG 
recovery (%)
Post-UF 
recovery (%)
PRLPEG 
[ng/mL]
PRLUF 
[ng/mL] Treatment
1. M/22 Macroprolactinoma Loss of libido 1,0540 29 58 3100 6087 brc
2. M/28 Macroprolactinoma Loss of libido 554 75 38 413 208 brc
3. M/52 Macroprolactinoma Loss of libido 1,097 79 29 861 319 brc
4. F/22 PCOS Oligomenorrhea 57 39 37 22 21 brc
5. F/20 PCOS Oligomenorrhea 80 29 40 23 32 brc
6. F/37 PCOS Oligomenorrhea 170 38 36 64 62 brc
7. F/30 HPRL Infertility 115 77 36 87 41 brc
8. F/18 HPRL – 129 18 17 23 20 brc
9. F/31 HPRL – 87 18 38 16 33 brc
10. F/29 HPRL – 80 31 38 25 30 brc
HPRL — idiopathic hyperprolactinaemia; PCOS — polycystic ovary syndrome; post-PEG recovery — recovery of PRL after PEG precipitation; 
post-UF recovery — recovery of PRL after ultrafiltration; PRLPEG — PRL level after PEG precipitation; PRLUF — PRL level after ultrafiltration; 
brc — bromocriptine
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In the group without significant amounts of MaPRL 
(110 subjects), we noted that after the removal of the 
macroforms of the hormone, the level of PRL was 
within the reference range in 12 patients (nine cases of 
PCOS and three subjects with HPRL). However, five of 
these subjects (42%) did not have clinical symptoms of 
hyperprolactinaemia (Table IV).
Discussion
Macroprolactinaemia occurs only sporadically in 
a healthy population [28, 29]. However, significant 
amounts of MaPRL have been found in hyperprolacti-
naemic subjects [9, 16, 20, 30 –32]. The incidence of macro-
prolactinaemia depends on the examined population and 
the method of MaPRL detection. It has been documented 
that in the United States about 10% of hyperprolacti-
naemic patients have MaPRL as a predominant form of 
PRL [33, 34]. Most of the studies conducted in Europe 
have shown that the frequency of macroprolactinae-
mia is usually above 20% [13, 14, 35, 36]. In the present 
study, significant amounts of MaPRL were detected in 
8% by evaluating with both methods and in only 5.8 % 
confirmed by PEG precipitation alone, which seems to 
be a rather low rate in comparison with the results men-
tioned above. In comparison with the results of other 
Polish investigators, we have found a lower frequency 
of macroprolactinaemia in subjects with idiopathic hy-
perprolactinaemia (9.3% vs. 25% and 34%) [37, 38]. We 
have used a similar precipitation procedure but different 
immunoassay (Immulite 1000 vs. Immunotech) and we 
noticed that in patients with HPRL in our group, the basal 
concentration of PRL was lower than in the work of the 
Warsaw group [37]. Conversely, Jeske et al. [37] obtained 
a two thirds lower frequency of macroprolactinaemia 
(4% vs. 12%) in patients with prolactinoma. But when 
we presume that dominancy of MaPRL confirmed by 
PEG precipitation concerns only one patient, we have 
exactly the same frequency — 4%. The gold standard for 
estimating various forms of PRL is gel chromatography, 
but in routine laboratory work, precipitation with PEG 
is applied more often. However, PEG treatment is not 
a perfect technique for detecting MaPRL because PEG 
may precipitate not only macroforms of PRL but also 
some monomeric PRL. Furthermore, PEG may cause 
immunoassay interference on the analysers, including 
Immulite which was used to measure PRL concentra-
tion in our study [21, 22, 36]. Therefore, screening for 
macroprolactinaemia may sometimes require other 
techniques. One of the proposed methods is centrifugal 
ultrafiltration. There are only a few papers concerning 
ultrafiltration in world literature [21, 23–25, 27]. In our 
study, we noted a positive correlation and a general 
high diagnostic concordance between the investigated 
methods. We observed that in patients with functional 
hyperprolactinaemia, the results of both methods based 
Table IV. Characteristics of patients who have real PRL concentration in reference range
Tabela IV. Charakterystyka pacjentów, u których rzeczywiste stężenie PRL mieściło się w zakresie wartości referencyjnych
No. Sex/age Clinical 
diagnosis
Clinical 
symptoms 
of HPRL
PRL 
[ng/mL]
Post-PEG 
recovery (%)
Post-UF 
recovery (%)
PRLPEG 
[ng/mL]
PRLUF 
[ng/mL]
Treatment
1. F/35 PCOS Oligomenorrhea 37 58 67 22 25 brc
2. F/32 PCOS Oligomenorrhea 36 61 71 22 25 brc
3. F/18 PCOS Oligomenorrhea 39 76 59 29 23 brc
4. F/20 PCOS Oligomenorrhea 31 77 76 24 24 brc
5. F/24 PCOS Oligomenorrhea 35 70 72 24 25 brc
6. F/25 PCOS Oligomenorrhea 51 49 55 25 28 brc
7. F/24 PCOS Gallactorrhea 40 62 84 24 33 brc
8. F/29 PCOS – 36 60 62 21 22 brc
9. F/28 PCOS – 50 64 48 32 24 brc
10. F/13 HPRL –  32 66 82 21 26 brc
11. F/20 HPRL – 35 78 65 28 23 brc
12. F/24 HPRL – 48 56 49 27 24 brc
HPRL — idiopathic hyperprolactinaemia; PCOS — polycystic ovary syndrome; PRL — concentration of PRL after using precipitation or ultrafiltration 
method; post-PEG recovery — recovery of PRL after PEG precipitation; post-UF recovery — recovery of PRL after ultrafiltration; PRLPEG — PRL level after 
PEG precipitation; PRLUF — PRL level after ultrafiltration; brc — bromocriptine
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on a 40% cut-off point were all concordant, except for 
one case. However, in patients with pituitary adenoma, 
the results of precipitation and ultrafiltration vary con-
siderably. Previous studies have shown a disagreement 
in recovery after ultrafiltration compared to PEG pre-
cipitation for samples without macroprolactin;  in such 
cases, the results of ultrafiltration may exhibit apparent 
(false-positive) macroprolactinaemia [21, 23, 25]. 
In our study, such a situation might concern two pa-
tients with pituitary adenoma (No. 2 and 3 — Table III) 
and a woman with idiopathic hyperprolactinaemia 
(No.7 — Table III) — where the well-established pre-
cipitation method indicated that there was no MaPRL 
domination in their sera. The lower hormone recovery 
seen after ultrafiltration than after precipitation can be 
explained by the fact that in some cases of hyperpro-
lactinaemia with high concentrations of PRL (higher 
than 100 ng/mL) the passage of different forms of PRL 
through the separating membrane during ultrafiltra-
tion depends not only on their molecular size, but 
also on net charge and three-dimensional structure of 
particles [25]. On the other hand, the lower hormone 
recovery after precipitation than after ultrafiltration (in 
our study — patient No. 1 — Table III) may be due to 
the co-precipitation of monomeric PRL and “big PRL” 
by PEG. This may lead to an underestimation of mo-
nomeric PRL concentrations by 25% or even more [21, 
39]. Moreover, according to the manufacturer of the 
Microcon ultrafilter, during the ultrafiltration almost 
all molecules up to 45 kDa freely cross the membrane 
of the filtration unit, but only 50% of particles with 
molecular weight, like “big PRL” (~60kDa), do so 
(Microcon leaflet). 
Hyperprolactinaemia in women with PCOS has been 
widely described for decades but the mechanism of this 
coexistence remains largely unknown [40–44]. Recent 
studies have even suggested that the elevation of PRL 
concentration and PCOS are independent disorders and 
they recommend that patients should be investigated 
for other causes of hyperprolactinaemia [45, 46]. Our 
results showed that PRL concentration in PCOS was very 
similar to idiopathic hyperprolactinaemia. Moreover, 
the recoveries of PRL after PEG precipitation and after 
ultrafiltration were comparable (Table I). However, the 
occurrence of macroprolactinaemia in PCOS women was 
the lowest among three examined groups (5.8% vs. 12% 
for prolactinoma and 9.3% for HPRL). 
From the clinical point of view, it is important to re-
alise that the statement of macroprolactinaemia does not 
exclude hyperprolactinaemia. Especially in patients with 
high basal PRL concentration, recovery of PRL of lower 
than 40% may occur, but real hormone concentration, 
after macroforms separation, may be still above the refer-
ence range. Here, treatment with appropriate drugs, such 
as dopamine agonists, should be applied. On the other 
hand, in patients who have even a small number of mac-
roforms (recovery higher than 40%) it may turn out that 
real PRL concentrations remain in the reference range. In 
our study, this situation has concerned 12 subjects (10%) 
— Table IV. Some of them (~ 40%) have no clinical symp-
toms of hyperprolactinaemia and probably those patients, 
similarly to subjects with macroprolactinaemia, have not 
required drugs which inhibit the secretion of PRL. 
In conclusion, we can state that screening for MaPRL 
should be performed in hyperprolactinaemic sera, par-
ticularly in non-organic hyperprolactinaemia. Although 
the Immulite test for the measurement of PRL is clas-
sified as a “middle-reacting” assay with MaPRL [36], 
our results show that macroprolactinaemia in hyperp-
rolactinaemic patients seems not to be a major clinical 
problem because the frequency of macroprolactinaemia 
in our study was rather low. 
Moreover, on the basis of the findings, we can con-
clude that the effectiveness of the precipitation and the 
ultrafiltration methods for detecting MaPRL is compa-
rable in functional hyperprolactinaemia, but the useful-
ness of ultrafiltration in patients with pituitary adenoma 
requires further examination, including the verification 
of obtained results by using gel chromatography.
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